[{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"73e8506b-a82d-41df-b4ff-414021e9babc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03042221","created_at":"2021-01-18T14:58:44.313Z","updated_at":"2025-02-25T16:36:51.399Z","phase":"","brief_title":"Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy","source_id_and_acronym":"NCT03042221","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion","tags":["BRAF • ALK • ROS1 • CD8 • CDH1 • CD14 • VIM • MRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • ROS1 fusion"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/10/2016","start_date":" 05/10/2016","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"d934aafe-bd3e-4728-955c-fb7a4b80ce12","acronym":"HRPCa-II","url":"https://clinicaltrials.gov/study/NCT05333432","created_at":"2022-04-19T23:53:47.960Z","updated_at":"2025-02-25T17:37:45.989Z","phase":"","brief_title":"Evaluation of a Multimodal Strategy for Early Diagnosis of Men At High Genetic Risk of Prostate Cancer","source_id_and_acronym":"NCT05333432 - HRPCa-II","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13","pipe":" | ","alterations":" PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 880","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-01-28"},{"id":"8d1ccb5b-f750-498e-b8e0-01cc46ef60cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919108","created_at":"2023-06-26T14:09:19.440Z","updated_at":"2024-07-02T16:34:26.575Z","phase":"Phase 2","brief_title":"Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers","source_id_and_acronym":"NCT05919108","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • CDH1","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 04/30/2030","primary_completion_date":" 04/30/2030","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2024-06-13"},{"id":"2278f5bb-b153-48d6-8bef-dfa2d6d4b72e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04535414","created_at":"2021-01-18T21:42:30.401Z","updated_at":"2024-07-02T16:34:58.809Z","phase":"Phase 2","brief_title":"Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers","source_id_and_acronym":"NCT04535414","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 06/22/2023","start_date":" 06/22/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-06-05"},{"id":"8a617f1a-04a1-44fa-9406-0c4b9b9170e3","acronym":"BEAUTY","url":"https://clinicaltrials.gov/study/NCT03979508","created_at":"2021-01-18T19:34:12.469Z","updated_at":"2024-07-02T16:35:07.182Z","phase":"Phase 2","brief_title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","source_id_and_acronym":"NCT03979508 - BEAUTY","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1","pipe":" | ","alterations":" JAK2 amplification","tags":["HER-2 • ER • PGR • CD20 • JAK2 • CD8 • CDH1 • CCR4 • IL2RA • PTPRC • NCAM1 • CCR5 • CCR7 • CD14 • CD27 • GZMB • HLA-B • NLRC5 • FOXP3 • IKZF2 • IL3RA • STAT1 • CXCR3 • CXCR5 • ITGAX • PRF1 • SNAI2 • TAP1 • CCR6 • CEACAM8 • DDX58 • HLA-C • IFNL1 • IFNL2 • IFNL3 • ITGB1 • KLRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-04-29"},{"id":"5d0f978b-61f7-4e60-b450-92e2db41b6c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04257045","created_at":"2021-01-18T20:41:29.194Z","updated_at":"2024-07-02T16:35:19.446Z","phase":"","brief_title":"Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives","source_id_and_acronym":"NCT04257045","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • EPCAM • BARD1 • DICER1","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • EPCAM • BARD1 • DICER1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 08/21/2019","start_date":" 08/21/2019","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-02-14"},{"id":"d6f98f26-2498-46cc-812f-de883aab657a","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT03306472","created_at":"2021-01-18T16:19:53.588Z","updated_at":"2024-07-02T16:35:21.649Z","phase":"Phase 2","brief_title":"A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","source_id_and_acronym":"NCT03306472 - PIONEER","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1 • CDH2","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1 • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • megestrol"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 07/20/2017","start_date":" 07/20/2017","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-01-30"},{"id":"4c92b32e-341b-4687-bdb2-e542cce6f6c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04821141","created_at":"2021-03-29T11:52:25.247Z","updated_at":"2024-07-02T16:35:22.098Z","phase":"Phase 2","brief_title":"Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens","source_id_and_acronym":"NCT04821141","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN","pipe":" | ","alterations":" PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation","tags":["BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-01-26"},{"id":"5479908c-ebf1-4d0f-ac1d-6ffcc61f3478","acronym":"LISA-HDGC","url":"https://clinicaltrials.gov/study/NCT04253106","created_at":"2021-01-18T20:40:03.374Z","updated_at":"2024-07-02T16:35:23.768Z","phase":"","brief_title":"Liquid Biopsies for the Personalized Management of Patients With Hereditary Diffuse Gastric Cancer","source_id_and_acronym":"NCT04253106 - LISA-HDGC","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" CDH1 • CTNNA1","pipe":"","alterations":" ","tags":["CDH1 • CTNNA1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 11/26/2024","primary_completion_date":" 11/26/2024","study_txt":" Completion: 11/26/2024","study_completion_date":" 11/26/2024","last_update_posted":"2024-01-11"},{"id":"49e68145-ee70-4d53-9957-c38dd7f689fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01034033","created_at":"2021-01-18T04:03:34.909Z","updated_at":"2024-07-02T16:35:24.040Z","phase":"","brief_title":"Genetic \u0026 Pathological Studies of BRCA1/BRCA2: Associated Tumors \u0026 Blood Samples","source_id_and_acronym":"NCT01034033","lead_sponsor":"Stanford University","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • CDH1","pipe":" | ","alterations":" TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN mutation","tags":["TP53 • BRCA1 • BRCA2 • PTEN • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA2 mutation • BRCA1 mutation • PTEN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 3300","initiation":"Initiation: 08/01/2001","start_date":" 08/01/2001","primary_txt":" Primary completion: 01/01/2099","primary_completion_date":" 01/01/2099","study_txt":" Completion: 01/01/2099","study_completion_date":" 01/01/2099","last_update_posted":"2024-01-09"},{"id":"d0a5b583-cfde-45fb-82fc-849fca7b6951","acronym":"","url":"https://clinicaltrials.gov/study/NCT00582257","created_at":"2021-01-18T02:08:30.161Z","updated_at":"2024-07-02T16:35:24.446Z","phase":"","brief_title":"Early Onset and Familial Gastric Cancer Registry","source_id_and_acronym":"NCT00582257","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 971","initiation":"Initiation: 12/01/2005","start_date":" 12/01/2005","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-05"},{"id":"bd544bf4-745a-4b82-abc5-b542c9fc7a34","acronym":"ROLo","url":"https://clinicaltrials.gov/study/NCT03620643","created_at":"2021-01-18T17:47:27.839Z","updated_at":"2024-07-02T16:35:25.368Z","phase":"Phase 2","brief_title":"Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours","source_id_and_acronym":"NCT03620643 - ROLo","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • CDH1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • CDH1 mutation • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/09/2019","start_date":" 05/09/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-12-22"},{"id":"b7fe2456-c3ca-418e-bec6-60cb1309b501","acronym":"LobularCard","url":"https://clinicaltrials.gov/study/NCT05410951","created_at":"2022-06-08T11:58:18.736Z","updated_at":"2024-07-02T16:35:36.292Z","phase":"","brief_title":"LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients","source_id_and_acronym":"NCT05410951 - LobularCard","lead_sponsor":"European Institute of Oncology","biomarkers":" HER-2 • BRCA1 • PTEN • CDH1","pipe":" | ","alterations":" PALB2 mutation","tags":["HER-2 • BRCA1 • PTEN • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 05/16/2022","start_date":" 05/16/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 05/16/2027","study_completion_date":" 05/16/2027","last_update_posted":"2023-09-21"},{"id":"e0ff64e5-f5f3-48fe-8823-ec69c14bf5dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04206891","created_at":"2021-01-18T20:29:28.352Z","updated_at":"2024-07-02T16:35:36.326Z","phase":"","brief_title":"CDH1 Germline Mutations in Lobular Breast Cancer","source_id_and_acronym":"NCT04206891","lead_sponsor":"European Institute of Oncology","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 421","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2023-09-21"},{"id":"14cd3a07-5308-40ed-ab07-6f32d094431e","acronym":"CAPSBRACA","url":"https://clinicaltrials.gov/study/NCT03729115","created_at":"2021-01-18T18:16:15.751Z","updated_at":"2024-07-02T16:35:41.079Z","phase":"","brief_title":"A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer","source_id_and_acronym":"NCT03729115 - CAPSBRACA","lead_sponsor":"University of Chicago","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • STK11 • CDH1","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • PTEN • STK11 • CDH1"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-08-03"},{"id":"de733c73-a0d7-47e0-af3c-13fad6bdb8a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00989638","created_at":"2021-01-18T03:51:58.115Z","updated_at":"2024-07-02T16:35:49.383Z","phase":"","brief_title":"A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer","source_id_and_acronym":"NCT00989638","lead_sponsor":"University of Chicago","biomarkers":" TP53 • BRCA1 • BRCA2 • PTEN • BRCA • CDH1 • CHEK2","pipe":"","alterations":" ","tags":["TP53 • BRCA1 • BRCA2 • PTEN • BRCA • CDH1 • CHEK2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 305","initiation":"Initiation: 06/23/2004","start_date":" 06/23/2004","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2023-04-28"},{"id":"e6fa6f5f-f47f-4e45-ac2a-8106517e9c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT04021394","created_at":"2021-01-18T19:44:45.886Z","updated_at":"2024-07-02T16:35:51.538Z","phase":"","brief_title":"Influence of EMT on CTCs and Disease Progression in Prostate Cancer","source_id_and_acronym":"NCT04021394","lead_sponsor":"Lawson Health Research Institute","biomarkers":" CDH1 • EPCAM • CDH2 • ZEB1","pipe":" | ","alterations":" AR expression • CDH1 expression • EPCAM expression • ZEB1 expression","tags":["CDH1 • EPCAM • CDH2 • ZEB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • CDH1 expression • EPCAM expression • ZEB1 expression"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 04/27/2021","primary_completion_date":" 04/27/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-04-04"},{"id":"513233c3-4e61-45fc-aea5-4e9b44e4a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01514045","created_at":"2021-01-18T06:21:47.928Z","updated_at":"2024-07-02T16:35:54.729Z","phase":"","brief_title":"The Gastric Cancer Foundation: A Gastric Cancer Registry","source_id_and_acronym":"NCT01514045","lead_sponsor":"Stanford University","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 mutation","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-02-24"},{"id":"67668528-5408-4edc-9d86-1a1632971ecf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777943","created_at":"2021-01-18T18:41:15.452Z","updated_at":"2024-07-02T16:35:59.268Z","phase":"","brief_title":"Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis","source_id_and_acronym":"NCT03777943","lead_sponsor":"University Ghent","biomarkers":" VEGFA • MSLN • WT1 • CDH1 • ICAM1 • VCAM1","pipe":"","alterations":" ","tags":["VEGFA • MSLN • WT1 • CDH1 • ICAM1 • VCAM1"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 03/28/2022","primary_completion_date":" 03/28/2022","study_txt":" Completion: 03/28/2022","study_completion_date":" 03/28/2022","last_update_posted":"2022-12-12"},{"id":"290b7fc0-2551-4b8e-8a40-119d81d3738c","acronym":"VitDURO","url":"https://clinicaltrials.gov/study/NCT04197089","created_at":"2021-01-18T20:27:15.791Z","updated_at":"2024-07-02T16:36:06.166Z","phase":"Phase 4","brief_title":"Biological Effect of Vitamin D in Patients With Urothelial Carcinoma","source_id_and_acronym":"NCT04197089 - VitDURO","lead_sponsor":"Germans Trias i Pujol Hospital","biomarkers":" FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5","pipe":"","alterations":" ","tags":["FGFR3 • CDH1 • CD14 • CDH2 • KRT14 • CDKN1A • G0S2 • GAPDH • KRT20 • KRT5"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 11/22/2021","primary_completion_date":" 11/22/2021","study_txt":" Completion: 11/22/2021","study_completion_date":" 11/22/2021","last_update_posted":"2022-08-03"},{"id":"20481648-b24a-4001-9d26-bf1b3e73c61c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451553","created_at":"2021-01-18T11:45:16.896Z","updated_at":"2024-07-02T16:36:09.285Z","phase":"Phase 1","brief_title":"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer","source_id_and_acronym":"NCT02451553","lead_sponsor":"University of Washington","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 04/16/2022","primary_completion_date":" 04/16/2022","study_txt":" Completion: 04/16/2022","study_completion_date":" 04/16/2022","last_update_posted":"2022-06-07"},{"id":"66171eb4-84d6-423c-9850-421ced68c0b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05362539","created_at":"2022-05-05T15:53:50.233Z","updated_at":"2024-07-02T16:36:10.939Z","phase":"","brief_title":"Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria","source_id_and_acronym":"NCT05362539","lead_sponsor":"Mansoura University","biomarkers":" CDH1 • CD99","pipe":"","alterations":" ","tags":["CDH1 • CD99"],"overall_status":"Completed","enrollment":" Enrollment 246","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2022-05-05"},{"id":"a25a7657-8064-40e7-806c-f6d355167a9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05042531","created_at":"2021-09-13T14:55:55.634Z","updated_at":"2024-07-02T16:36:11.575Z","phase":"","brief_title":"Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia","source_id_and_acronym":"NCT05042531","lead_sponsor":"LanZhou University","biomarkers":" TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A","pipe":"","alterations":" ","tags":["TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/13/2021","start_date":" 11/13/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-04-25"}]